We advised Nanoform Finland Plc in connection with a directed share issue of approximately EUR 25 million through an accelerated book building procedure.
Nanoform successfully completed the share issue on 22 March 2022. The next step for the company is to prepare for GMP manufacturing in the USA, the world’s largest pharmaceutical market.
The accelerated book building to Nordic and international institutional and other qualified investors was carried out based on offers received in an accelerated book building procedure.
Nanoform is an innovative company that contributes to the development of nanoparticle medicine. Nanoform works together with pharmaceutical and biotech partners worldwide to provide hope for patients by enabling the development of new and improved medicines utilising Nanoform’s platform technologies.